No prescription sales. No commercial bias.  — An independent publication. Editorial content funded by affiliated stores. How we work →

Research compounds

What the evidence actually shows

No vendor bias. Balanced analysis of preliminary and emerging research.

Research use only. The compounds described here are sold for research purposes only and are not approved for human therapeutic use by the FDA. This content is informational and does not constitute medical advice.

BPC-157

Evidence: Preliminary

Body Protection Compound-157 is a synthetic peptide derived from a gastric protein. Animal models show accelerated gut healing and anti-inflammatory effects. Human evidence is sparse — primarily case reports and small open-label studies with no control groups.

Med spas market it aggressively as a GI side-effect cure for GLP-1 users. The FDA has flagged immunogenicity concerns in compounding guidance. Honest assessment: interesting mechanism, insufficient human evidence to make confident claims, legitimate safety questions that vendors downplay.

TB-500 (Thymosin Beta-4 fragment)

Evidence: Preliminary

A synthetic fragment of thymosin beta-4 with reported tissue repair and anti-inflammatory properties in animal models. Often stacked with BPC-157. Human trials are limited to small case series.

Where to find COA-verified compounds

We disclose our affiliation with CMPD Health, which sells third-party tested research compounds with published COAs for every batch. We recommend them because we know the testing protocol — HPLC purity ≥99%, every batch published.